Key Metrics
Journal Specifications
- PublisherPHARMACEUTICAL SOC JAPAN
- LanguageJapanese
- FrequencyMonthly
- LanguageJapanese
- FrequencyMonthly
- Publication Start Year1970
- Publisher URL
- Website URL
Ready to spotlight your research findings?
Impress peers and journals alike with a concise, visual summary of your work.
Topics Covered
Year-wise Publication
- 5Y
- 10Y
FAQs
Since when has Yakugaku Zasshi been publishing? 
The Yakugaku Zasshi has been publishing since 1970 till date.
How frequently is the Yakugaku Zasshi published? 
Yakugaku Zasshi is published Monthly.
Who is the publisher of Yakugaku Zasshi? 
The publisher of Yakugaku Zasshi is PHARMACEUTICAL SOC JAPAN.
How can I view the journal metrics of Yakugaku Zasshi on editage? 
For the Yakugaku Zasshi metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of Yakugaku Zasshi? 
The eISSN number is 1347-5231 and pISSN number is 0031-6903 for Yakugaku Zasshi.
What is the focus of this journal? 
The journal covers a wide range of topics inlcuding Heart failure, Down syndrome, Drug discovery, Osteoporosis, Drug, Pharmaceutical sciences, Japanese Pharmacopoeia, Knowledge sharing, Pharmacy, Irradiation, Simulation, Lipopolysaccharide, Carboxylic acid, Health literacy, Infection control, Brain development, Questionnaire, Cancer, Renal function, Cerebral cortex.
Why is it important to find the right journal for my research? 
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career? 
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only? 
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.